Skip to main content

Puma Biotechnology Inc. (PBYI)

NASDAQ: PBYI · Delayed Price · USD
5.81
-0.08 (-1.36%)
Pre-market:Oct 22, 2021 7:32 AM EDT
5.89
-0.02 (-0.34%)
At close: Oct 21, 4:00 PM
Market Cap242.84M
Revenue (ttm)254.86M
Net Income (ttm)-35.04M
Shares Out40.48M
EPS (ttm)-0.88
PE Ration/a
Forward PE22.78
Dividendn/a
Ex-Dividend Daten/a
Volume232,941
Open5.86
Previous Close5.91
Day's Range5.86 - 6.00
52-Week Range5.84 - 14.14
Beta1.14
AnalystsHold
Price Target8.43 (+43.1%)
Est. Earnings DateNov 4, 2021

About PBYI

Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company's drug candidates include PB272 neratinib (oral) for the adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer; PB272 (neratinib, oral) for the use of neratinib in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer; PB272 (neratinib, oral) for...

IndustryBiotechnology
Founded2010
Employees267
Stock ExchangeNASDAQ
Ticker SymbolPBYI
Full Company Profile

Financial Performance

In 2020, PBYI's revenue was $225.11 million, a decrease of -17.32% compared to the previous year's $272.26 million. Losses were -$60.00 million, -20.64% less than in 2019.

Financial Statements

Analyst Forecast

According to 10 analysts, the average rating for PBYI stock is "Hold." The 12-month stock price forecast is 8.43, which is an increase of 43.12% from the latest price.

Price Target
$8.43
(43.12% upside)
Analyst Consensus: Hold

News

Puma Biotechnology to Host Conference Call to Discuss Third Quarter Financial Results

LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, will host a conference call at 1:30 p.m. PDT/4:30 p.m. EDT on Thursday, Nov. 4, 2021, following the re...

16 hours ago - Business Wire

Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology reported inducement awards granted in Sept. 2021 to six non-executive employees, as required under Nasdaq Listing Rule 5635(c)(4).

2 weeks ago - Business Wire

Puma Biotechnology to Present at the Cantor Virtual Global Healthcare Conference

LOS ANGELES--(BUSINESS WIRE)--Alan Auerbach will present an overview of Puma Biotechnology at 8:00 a.m. EDT on Sept. 28, at the 2021 Cantor Virtual Global Healthcare Conference.

1 month ago - Business Wire

Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

LOS ANGELES--(BUSINESS WIRE)--On Sept. 7, 2021, Puma Biotechnology reported inducement awards granted to new staff in August, as required by Nasdaq Listing Rule 5635(c)(4) .

1 month ago - Business Wire

Puma Biotechnology to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

LOS ANGELES--(BUSINESS WIRE)--Alan Auerbach will present an overview of Puma Biotechnology at the H.C. Wainwright 23rd Annual Global Investment Conference beginning on Sept. 13.

1 month ago - Business Wire

Puma (PBYI) Q2 Loss Narrower Than Expected, Nerlynx View Cut

Puma Biotech (PBYI) reports better-than-expected Q2 earnings and sales. It lowers 2021 Nerlynx sales guidance.

2 months ago - Zacks Investment Research

Puma Biotech (PBYI) Reports Q2 Loss, Tops Revenue Estimates

Puma Biotech (PBYI) delivered earnings and revenue surprises of 58.06% and 4.69%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

2 months ago - Zacks Investment Research

Puma Biotechnology Reports Second Quarter 2021 Financial Results

LOS ANGELES--(BUSINESS WIRE)--Puma biotechnology reported financial results for the second quarter of 2021 , followed by a conference call on August 5, 2021.

2 months ago - Business Wire

Earnings Preview: Puma Biotech (PBYI) Q2 Earnings Expected to Decline

Puma Biotech (PBYI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 months ago - Zacks Investment Research

Puma Biotechnology Secures $125 Million Note Purchase by Athyrium Capital

LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology and Athyrium Capital have entered into an agreement for the issuance of up to $125 million of notes in two tranches.

2 months ago - Business Wire

Puma Biotechnology to Host Conference Call to Discuss Second Quarter Financial Results

LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology will host a conference call at 1:30 p.m. PT on Aug. 5 following the release of its second quarter 2021 financial results.

2 months ago - Business Wire

Puma Biotech's Nerlynx Wins Canadian Approval In HER2-Positive Metastatic Breast Cancer

Health Canada has approved Puma Biotechnology Inc's (NASDAQ: PBYI) Nerlynx (neratinib) in combination with capecitabine for metastatic HER2-overexpressed/amplified breast cancer, who have received two o...

3 months ago - Benzinga

Knight Therapeutics Announces Health Canada Approval for NERLYNX® (Neratinib) to Treat HER2-Positive Metastatic Breas...

MONTREAL, July 06, 2021 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD), (“Knight”) a pan-American (ex-USA) specialty pharmaceutical company, announced today that Health Canada has approved NERL...

3 months ago - GlobeNewsWire

Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology announced the grant of inducement restricted stock unit awards in June 2021, as required by Nasdaq Listing Rule 5635(c)(4) .

3 months ago - Business Wire

FDA Approves Dose Escalation Label Update for Puma Biotechnology's NERLYNX® (neratinib) in HER2-Positive Early Stage ...

LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology received FDA approval to include dose escalation in the NERLYNX label for both early stage and metastatic breast cancer patients.

3 months ago - Business Wire

Puma Biotechnology Presents Data from the EGFR Exon 18-mutant NSCLC Cohort of the Phase II SUMMIT Trial at the 2021 A...

LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology presented data from the EGFR Exon 18-mutant NSCLC cohort of the Phase II SUMMIT Trial on June 4 at the 2021 ASCO Annual Meeting.

4 months ago - Business Wire

Puma Biotechnology Presents Data Comparing Findings from the Phase II CONTROL Trial with the Neratinib Arm of the Pha...

LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology presented data from the Phase II CONTROL Trial regarding neratinib dose escalation at the ASCO 2021 Annual Meeting.

4 months ago - Business Wire

Puma Biotechnology Presents Data from the Phase III ExteNET Trial in Early Stage HER2-Positive Breast Cancer Patients...

LOS ANGELES--(BUSINESS WIRE)--The P III ExteNET Trial shows improved outcomes in patients with HER2+ early stage breast cancer who received ≥ 11 months of treatment with neratinib.

4 months ago - Business Wire

Puma Biotechnology Announces Publication of Abstracts on Neratinib for the 2021 ASCO Annual Meeting

LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology announce the availability of three abstracts on the ASCO Annual Meeting website related to poster presentations on June 4, 2021.

5 months ago - Business Wire

Puma (PBYI) Beats on Q1 Earnings, Ups Nerlynx Sales View

Puma Biotech (PBYI) beats first-quarter estimates for both earnings and sales. Stock up.

5 months ago - Zacks Investment Research

Puma Biotech (PBYI) Q1 Earnings and Revenues Beat Estimates

Puma Biotech (PBYI) delivered earnings and revenue surprises of 37.93% and 31.03%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

5 months ago - Zacks Investment Research

Puma Biotechnology Reports First Quarter 2021 Financial Results

LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology released its financial results for the first quarter ended March 31, 2021, after market close on May 6, 2021.

5 months ago - Business Wire

Puma Biotech (PBYI) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

Puma Biotech (PBYI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

5 months ago - Zacks Investment Research

Puma Biotechnology to Host Conference Call to Discuss First Quarter Financial Results

LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology will host a conference call/webcast at 1:30 p.m. PDT on May 6, 2021, following release of its 1Q-2021 financial results.

5 months ago - Business Wire

Puma Biotech (PBYI) Down 6.3% Since Last Earnings Report: Can It Rebound?

Puma Biotech (PBYI) reported earnings 30 days ago. What's next for the stock?

6 months ago - Zacks Investment Research